If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

From AI to gene therapy, we reached out to industry experts to get their thoughts on the trends that will shape the biotech ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...